Last update Feb. 23, 2025

Midecamycin, Midecamycin Acetate

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Midecamycin is a macrolide antibacterial produced by Streptomyces mycarofaciens with actions and uses similar to those of erythromycin. Oral administration.

At the date of last update we found no published data on its excretion in breast milk.

Its pharmacokinetic data (large volume of distribution and moderately high molecular weight) make it unlikely to pass into breast milk in clinically significant quantities.

Until more data on this drug are available, safer known alternatives are preferable, especially in the neonatal period and in case of prematurity. 

Alternatives

  • Clarithromycin (Safe product and/or breastfeeding is the best option.)
  • Erythromycin (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Midecamycin, Midecamycin Acetate in other languages or writings:

Group

Midecamycin, Midecamycin Acetate belongs to this group or family:

Tradenames

Main tradenames from several countries containing Midecamycin, Midecamycin Acetate in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. > 90 %
Molecular weight 814 daltons
Protein Binding 15 - 45 %
VD 7.7 l/Kg
pKa 12.71 -
Tmax 0.5 - 1 hours
T½ 0.8 - 2 hours

References

  1. Midecamicina. Ficha técnica. 1999 Full text (in our servers)
  2. Periti P, Mazzei T, Mini E, Novelli A. Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part I). Clin Pharmacokinet. 1989 Abstract

Total visits

7,815

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by AELAMA of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM